Clinical Trials · NCT03197012

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Name: Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedEARLY_Phase 1Octreotide

Phase: EARLY_Phase 1
Recruitment status: Completed
Sponsor: Thomas Hope
Enrollment: 10
Start date: Jul 2017
Locations: 1 site, United States
Primary endpoint: Overall Response Rate (ORR)

View Octreotide compound reference